Ulla S Puistola - Gynecology

Author Information

Ulla S. Puistola is a prominent researcher affiliated with the Department of Obstetrics and Gynecology at the PEDEGO Research Unit, Medical Research Center Oulu, University of Oulu, and University Hospital of Oulu in Finland. Her research primarily focuses on the intersection of gynecology and metabolic disorders, particularly examining the implications of diabetes and related medications on cancer prognosis and incidence.

Research Contributions

Ulla S. Puistola has made significant contributions to understanding the relationship between antidiabetic medications, statins, and cancer outcomes in women, particularly those with type 2 diabetes. Her work includes exploring the prognosis of endometrial and breast cancer in the context of diabetes and the impact of medications like metformin on cancer aggressiveness and survival rates. Her research is instrumental in providing insights into how metabolic health influences cancer progression and patient outcomes.

Aliases

Throughout her academic career, Ulla S. Puistola has been referenced by several name variations including U. Puistola, U Puistola, and U. S. Puistola. These aliases represent the same researcher and are used interchangeably across different publications and citations.

Publication and Citation Metrics

Metric	Value
Total Citations	3008
H-Index	32
Total Papers	125

Publications:

No Association Between Statin Use and the Prognosis of Endometrial Cancer in Women With Type 2 Diabetes

DOI: 10.3389/fphar.2021.621180

Year: 2021

Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes

DOI: 10.1038/s41598-021-88488-x

Year: 2021

Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes

DOI: 10.21873/anticanres.14834

Year: 2021

Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer

DOI: 10.3389/pore.2021.1609936

Year: 2021

Association of Metformin, Other Antidiabetic Medications, and Statins With Incidence of Colon Cancer in Patients With Type 2 Diabetes.

DOI: 10.1016/j.clcc.2020.11.003

Year: 2020

Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study

DOI: 10.1080/0284186X.2020.1769858

Year: 2020

Metformin and ovarian cancer: the evidence.

DOI: 10.21037/ATM-20-1060

Year: 2020

Cytoplasmic Keap1 Expression Is Associated With Poor Prognosis in Endometrial Cancer

DOI: 10.21873/anticanres.13151

Year: 2019

Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes

DOI: 10.1177/1010428318815413

Year: 2019

Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes

DOI: 10.1007/s10549-019-05185-0

Year: 2019

How to Write Effective Endnotes?

What is a Well Woman Visit?

What Follow-Up Actions are Recommended After a Positive FTA-ABS Test?

What are the limitations and risks of PGD?

How is Optical Density Measured?

What is Diastasis Recti?

What Certifications Does the AAPC Offer for Gynecology Coders?

Why Is Hypoallergenic Important in Gynecology?

How Can Technology Enhance Tailored Care?

Is Tempeh Safe During Pregnancy?

Partnered Content Networks

Relevant Topics